Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 1996

View Archived Issues

Fujisawa discloses bradykinin antagonists

DuPont Merck and Richwood enter marketing agreement

Connective Therapeutics to develop new formulation of betamethasone valerate

ICN's Viquin Forte launched in U.S.

Zeneca's Merrem receives FDA clearance

Otsuka seeks approval for grepafloxacin HCl

Antibacterial agents revealed by Wakunaga

Pharmacia & Upjohn reveal antimicrobial phenyloxazolidinones

Antifungal agents revealed by Merck & Co.

Lidak's Lidakol undergoes phase III trials

CSL to distribute OraVax's HNK20

Merck & Co. claims process for synthesizing HIV protease inhibitors

Remune covered under Finnish patent

Viramune receives accelerated FDA approval

Hybridon's GEM-132 to undergo clinical trials

U.S. development of DS-4152 for Kaposi's sarcoma treatment discontinued

Sequus' Caelyx approved by European Commission

Zithromax approved by FDA for new indication

Second receptor for HIV infection reported

Atovaquone/proguanil combination shows efficiency and safety

COX-2 inhibitors from Merck Frosst

Menarini's Enantyum launched in Spain

Connective Therapeutic's ConXn undergoes phase II trial

AlloMune undergoes clinical research

PT-11061 reported by Isis

SKI-2054R synthesized by Sunkyong

Agouron and Roche sign codevelopment agreement

DepoCyt earns positive phase III results

Antitumor taxoids revealed

More antitumor taxoids

LHRH antagonists from TAP Holdings

Eulexin is FDA-approved for new indication

Therapeutic melanoma vaccine in phase I

Virulizin undergoes phase I/II in pancreatic cancer

Marimastat enters U.S. and U.K. phase III trial

Antitumor epidioxymanadic acid described by Pharma Mar

MT-332: Pharma Mar's novel cytotoxic metabolite

Antineoplastic/antifungal agent revealed

Pan-agonist retinoid described by Ligand

Potential photodynamic therapy described

Pharmacyclic's Gd-Tex enhances radiation therapy

PEG-hemoglobin undergoes trial

Phase III trial for Fortical approved in U.K.

Apolipoprotein B synthesis inhibitors reported

SomatoKine covered under U.S. patent

HemAssist to enter phase III

Positive results for AD7C

Novel cervical cancer screening under evaluation

Trinity Biotech and SmithKline Beecham sign marketing agreement

Hemagen Diagnostics HIV research

Brain monoamine partial agonists/antagonists claimed by Neurogen

Ciba-Geigy and Synaptic extend collaboration

Gensia receives first payment from Pfizer

3-D IMP dehydrogenase structure solved

Boston Life Science holds patent rights to C-Maf

Oxford Molecular Group and Alizyme begin research collaboration

Hoechst, Hoechst Marion Roussel and Oncogene Science extend collaboration

Alizyme issued BTG license option

Collaboration for oral insulin formulation development

Techniclone's TNT to undergo clinical trials

American Biogenetic Sciences obtains antibody technology from MRC

Tripos' ChemSpace available for licensing soon

Organogenesis and MGH to collaborate on LAD development

Meridian Diagnostics purchases Cambridge Biotech enteric product line

Targeted Genetics acquires RGene Therapeutics

Dimethaid Research to invest in Oxo Chemie

Faulding acquires Cenovis

ChromaXome acquired by Houghten

RhoMed/Interfilm merger complete

TV-1901 demonstrates efficiency and safety

Gensia's GP-3269 in phase I

Depakote receives FDA approval for new indication

Gabitril approved in France as add-on therapy

MACH discovered by Weizmann Institute

FDA clears Myotrophin early access program

FDA approves drug/device combination

Protein kinase inhibitors reported by Cephalon

Ampalex proves effective and safe

Takeda seeks German approval for idebenone

RPR reports glutamate antagonists

NMDA antagonists synthesized by Hoechst Marion Roussel

Suntory describes metabotropic glutamate antagonists

Cypros is granted U.S. patent for CPC-211 dosing regimen

Lifarizine shows positive results in efficacy/safety study

CRF earns positive results in phase I/II

Proctor & Gamble acquires Dura products

Leukotriene biosynthesis inhibitors from Merck Frosst

Abbott discloses 5-lipoxygenase inhibitors

5-lipoxygenase and cyclooxygenase inhibitors from Abbott

GCC-AP0341: Green Cross' eosinophilia inhibitor

Eisai's ER-27319: Potential in treating allergic diseases

Adenosine A3 antagonists from Merck & Co.

FK-506 undergoes phase II trials

Trials terminated for HyperGAM+ for Pseudomonas lung infections

Angiotensin II antagonists described by Sankyo

Endothelin antagonists in Kyowa Hakko's pipeline

Neurex seeks FDA approval for Corlopam

Sankyo will seek FDA approval for temocapril HCl in 1997

Phospholipase A2 inhibitors for atherosclerosis treatment

PLC Systems' CO2 Heart Laser deemed effective in angina patients

SmithKline Beecham antiarrhythmic research revealed

Norvasc labeling revised by FDA

Nippon Mining reports on HV1C3

BCH-2763: BioChem Therapeutic's novel thrombin inhibitor

Texas Biotechnology and Synthelabo enter new argatroban collaboration

Neutralase covered under Japanese patent

Fibrinogen antagonists in Terumo's pipeline

FK-633 in phase II trials

Generic triamterene/hydrochlorothiazide approved by FDA

Human Genome Sciences discloses polypeptide research

EGCg shows antibacterial properties against H. pylori

5-HT4 agonists in Nisshin Flour Milling's pipeline

PD-140548: Non-peptide cholecystokinin CCK-A antagonist

SciClone's Zadaxin receives approval in Phillippines

Nadolol/isosorbide monohydrate combination prevents rebleeding

Sankyo to file NDA for Noscal

Exocell granted U.S. patent for A717

Merck & Co. reveals growth hormone release promoters

Zonagen's Vasomax covered under U.S. patent

Vasodilator cream shows positive results in trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...